Afatinib
Sign in to save this workspacePrimary targets: EGFR, ERBB2_HER2, ERBB4_HER4 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.50
Gini
0.709
CATDS
0.020
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Afatinib. Strongest target: ERBB4_HER4 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | ERBB4_HER4 | 100.0% | 0.0% |
| 2 | EGFR | 100.0% | 0.0% |
| 3 | ERBB2_HER2 | 98.9% | 1.1% |
| 4 | BLK | 96.8% | 3.2% |
| 5 | TXK | 93.0% | 7.0% |
| 6 | EPHA6 | 93.0% | 7.0% |
| 7 | BTK | 88.6% | 11.4% |
| 8 | DDR1 | 87.5% | 12.5% |
| 9 | LCK | 83.5% | 16.4% |
| 10 | C_MER | 82.8% | 17.2% |
| 11 | LYN | 78.7% | 21.3% |
| 12 | P38A_MAPK14 | 78.1% | 21.9% |
| 13 | IRAK1 | 72.1% | 27.9% |
| 14 | ABL1 | 67.1% | 32.9% |
| 15 | HCK | 66.5% | 33.5% |
| 16 | C_MET | 65.7% | 34.3% |
| 17 | DYRK2 | 62.6% | 37.4% |
| 18 | PEAK1 | 59.8% | 40.2% |
| 19 | FGR | 59.2% | 40.8% |
| 20 | ITK | 58.7% | 41.3% |
Selectivity landscape
Where Afatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Afatinib.
Annotations
Sign in to read and post annotations.
Loading…